Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	29.60% 207.28	159.93	166.50	139.29	139.49
Operating Expenses	3.10% 320.56	330.82	274.38	282.23	271.48
Benefits Costs and Expenses	1.33% 334.96	339.47	280.50	289.06	272.71
Costs And Expenses	1.33% 334.96	339.47	280.50	289.06	272.71
Operating Income/Loss	33.71% -113.28	-170.89	-107.89	-142.94	-131.99
Income/Loss From Continuing Operations Before Tax	28.88% -127.69	-179.54	-114.00	-149.77	-133.21
Income Tax Expense/Benefit	0.34% 0.87	0.873	0.947	1.31	0.303
Income/Loss From Continuing Operations After Tax	28.74% -128.56	-180.41	-114.95	-151.08	-133.52
Net Income/Loss	28.74% -128.56	-180.41	-114.95	-151.08	-133.52
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	99.59% 0.4136	99.77	98.46	96.29	95.49
Diluted Average Shares	99.59% 0.4136	99.77	98.46	96.29	95.49
Basic Earnings Per Share	29.28% -1.28	-1.81	-1.17	-1.57	-1.40
Diluted Earnings Per Share	29.28% -1.28	-1.81	-1.17	-1.57	-1.40
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-